Slow Pump Adoption And Regulatory Risks Will Eventually Support A Stronger Automated Insulin Future

Catalysts

About Beta Bionics

Beta Bionics develops and commercializes automated insulin delivery systems, including the iLet insulin pump and a pipeline of diabetes devices and drug-device combinations.

What are the underlying business or industry changes driving this perspective?

• Although iLet is expanding the insulin pump market by bringing in users from multiple daily injections and gaining traction with healthcare providers, the process of changing provider habits in an underpenetrated pump market can be slow. This may limit how quickly new patient starts translate into sustained revenue growth.
• Although the shift to pharmacy reimbursement is building a high margin, recurring supply revenue base, the need for individual health plans to adopt iLet under the pharmacy benefit, despite broad PBM formulary agreements, could cap the pace of mix improvement and delay the full margin impact on earnings.
• While the Mint patch pump and the bihormonal system are positioned to build on automation and ease of use trends in diabetes care, regulatory complexity, manufacturing readiness and the need for long clinical drug trials may extend timelines. This could defer expected contributions to revenue and earnings.
• Although early 510(k) updates to iLet show the company can refine usability through software and over the air changes, ongoing investment in R&D, field sales and public company infrastructure raises operating expenses and may limit near term net margin expansion even as gross margin improves.
• While off label iLet use in type 2 diabetes and the broader push toward automated insulin delivery open a much larger addressable market, the absence of a formal type 2 label and potential future trial requirements could slow access to this group and temper the long term revenue and earnings impact.

Assumptions

This narrative explores a more pessimistic perspective on Beta Bionics compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts. How have these above catalysts been quantified?

• The bearish analysts are assuming Beta Bionics's revenue will grow by 37.7% annually over the next 3 years.
• The bearish analysts are not forecasting that Beta Bionics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Beta Bionics's profit margin will increase from -87.9% to the average US Medical Equipment industry of 12.6% in 3 years.
• If Beta Bionics's profit margin were to converge on the industry average, you could expect earnings to reach $29.1 million (and earnings per share of $0.63) by about January 2029, up from $-77.8 million today.
• In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 49.4x on those 2029 earnings, up from -10.1x today. This future PE is greater than the current PE for the US Medical Equipment industry at 31.1x.
• The bearish analysts expect the number of shares outstanding to grow by 1.56% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 7.68%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

• The market for insulin pumps in both type 1 and type 2 diabetes is described as very underpenetrated. If broader adoption of pump therapy across the industry is slower than expected, the pool of potential new iLet users could remain smaller for longer, which would affect revenue growth and the ability to scale earnings.
• The business depends heavily on expanding pharmacy reimbursement beyond current formulary agreements, but health plan level adoption is still limiting how many new patients actually use the pharmacy channel. If plans are slow to add iLet as a pharmacy benefit, the mix of higher margin recurring supply revenue could grow more slowly, which would weigh on gross margin and free cash flow.
• Future growth from the Mint patch pump and the bihormonal system relies on successful regulatory review, clinical work and manufacturing readiness. Management has acknowledged complex requirements around drug trials and coordination across multiple FDA centers, so any delay, redesign or unexpected data outcome could push out commercialization, which would defer expected contributions to revenue and earnings.
• The FDA Form 483 around complaint handling has already led to an increased volume of reportable events in the MAUDE database and a multi quarter remediation process. If investors, providers or regulators interpret the higher reported complaint count as a product quality issue, this could affect prescription trends and installed base retention, which would impact revenue and net margin.
• A meaningful portion of new patients are type 2 users starting iLet off label, but there is still no formal type 2 indication or clear timeline to pursue it. If future regulatory expectations for type 2 data are high or if competing systems with approved type 2 labels win share, iLet’s access to the large type 2 population could be restricted, which would limit long run revenue and earnings potential.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The assumed bearish price target for Beta Bionics is $25.0, which represents up to two standard deviations below the consensus price target of $31.8. This valuation is based on what can be assumed as the expectations of Beta Bionics's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
  
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $40.0, and the most bearish reporting a price target of just $25.0.
  
• In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $231.1 million, earnings will come to $29.1 million, and it would be trading on a PE ratio of 49.4x, assuming you use a discount rate of 7.7%.
  
• Given the current share price of $17.79, the analyst price target of $25.0 is 28.8% higher.
  
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.